Matrixx’s Zicam Sales Up, Ad Spend Burns Profits In Tough Cough/Cold Market
This article was originally published in The Tan Sheet
Executive Summary
First-quarter profits for Matrixx Initiatives were dragged down in part by increased ad spending in the face of a "sharp decline" in sales for the overall cough/cold category, Executive VP and CFO William Hemelt stated in an earnings call April 25